Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.42 - $3.24 $242 - $324
100 Added 25.0%
500 $1,000
Q2 2024

Aug 14, 2024

SELL
$2.28 - $3.03 $1,367 - $1,817
-600 Reduced 60.0%
400 $1,000
Q1 2024

May 15, 2024

SELL
$2.61 - $4.49 $7,047 - $12,123
-2,700 Reduced 72.97%
1,000 $2,000
Q4 2023

Feb 14, 2024

SELL
$1.97 - $4.21 $16,745 - $35,785
-8,500 Reduced 69.67%
3,700 $15,000
Q3 2023

Nov 14, 2023

SELL
$2.34 - $4.43 $2,106 - $3,986
-900 Reduced 6.87%
12,200 $38,000
Q2 2023

Aug 14, 2023

SELL
$1.9 - $4.3 $34,200 - $77,400
-18,000 Reduced 57.88%
13,100 $43,000
Q1 2023

May 15, 2023

BUY
$1.89 - $2.93 $41,958 - $65,046
22,200 Added 249.44%
31,100 $66,000
Q4 2022

Feb 14, 2023

BUY
$2.48 - $3.43 $22,072 - $30,527
8,900 New
8,900 $23,000

Others Institutions Holding ORGO

About Organogenesis Holdings Inc.


  • Ticker ORGO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 130,888,000
  • Market Cap $416M
  • Description
  • Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokin...
More about ORGO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.